Drug Profile

BBO 11818

Alternative Names: BBO-11818; Pan-KRAS inhibitor - BridgeBio Pharma

Latest Information Update: 29 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BridgeBio Pharma
Developer BridgeBio Oncology Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

20 Apr 2026 BBO 11818 receives Fast track status from the US FDA for Adenocarcinoma (Late stage disease)
06 Mar 2026 Pharmacodynamics data from a preclinical trial in Solid tumours released by the BridgeBio Oncology Therapeutics
07 Jan 2026 BridgeBio Pharma plans a combination trial with BBO 10203 later in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com